A study depicted that the onabotulinumtoxinA is beneficial for the reduction in headache-related impact, headache severity and improved quality of life other than headache treatment. It was illustrated that the treatment with onabotulinumtoxinA not only helps to reduce the headache days but also reduces the headache severity, headache-related impact and enhances the quality of life. 

The double-blind study shown the efficacy and tolerability of onabotulinumtoxinA for the prevention of headache in adults suffering from chronic migraine.

In this study, 24-week records were considered to find out the percentages of patients meeting the responder criteria for the variation in headache days, Headache Impact Test, MSQ Role Function-Restrictive and Average Daily Headache Severity.

The responders on HIT-6, MSQ-RFR and ADHS measures were considerably more patients treated with onabotulinumtoxinA as compared with placebo.

It was concluded that onabotulinumtoxinA for 24 weeks was able to provide benefits further than the decrease in headache days; including a decline in headache-related impact and headache severity and enhancement in the quality of life.